文献速递MDS 与骨髓增殖性肿瘤白血病

普通人群中DDX41基因变异的患病率及其意义

Prevalence and significance of DDX41 gene variants in the general population.
PubMed 文献 · Blood · 2023-01-01

在454792名英国生物银行参与者中鉴定出3538名(1/129)携带452种独特非同义DNA变异,1059名携带胚系致病性变异者中34例发生MDS/AML(比值比12.3)。DDX41致病性变异与MDS、AML及白血病家族史显著相关,与淋巴瘤、骨髓增殖性肿瘤或其他癌症无关。

要点

  • DDX41胚系致病性变异携带者MDS/AML风险升高,比值比12.3。
  • 起始丢失、截短和错义变异比值比分别为12.9、15.1和7.5。
  • 携带者克隆性造血患病率不增加,且克隆性造血在散发性MDS/AML前更常见。

核心结论

  • DDX41胚系致病性变异在普通人群中患病率约为1/129,与MDS/AML风险显著相关。
  • 克隆性造血在散发性MDS/AML前比DDX41突变型MDS/AML前更常见,提示不同演化路径。

研究设计与样本

  • 基于英国生物银行454792名参与者的遗传变异分析,鉴定出3538名个体携带452种独特非同义DNA变异。

主要发现

  • 1059名携带胚系致病性变异者中34例发生MDS/AML,非携带者比值比为12.3。
  • 起始丢失变异组218例中7例发生MDS/AML,比值比12.9;截短变异组584例中22例,比值比15.1;错义变异组257例中5例,比值比7.5。
  • 多变量逻辑回归显示DDX41胚系致病性变异与MDS、AML及白血病家族史显著相关,与淋巴瘤、骨髓增殖性肿瘤或其他癌症无关。
  • DDX41胚系致病性变异携带者克隆性造血患病率不增加;克隆性造血在散发性MDS/AML前比DDX41突变型MDS/AML前显著更常见。
  • 散发性与DDX41突变型AML基因组体细胞突变率无差异;较高的平均红细胞体积和血液DNA中体细胞DDX41突变可识别MDS/AML风险增加的携带者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Germ line variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis, and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454 792 United Kingdom Biobank (UKB) participants and identify 452 unique nonsynonymous DNA variants in 3538 (1/129) individuals. Many were novel, and the prevalence of most varied markedly by ancestry. Among the 1059 individuals with germ line pathogenic variants (DDX41-GPV) 34 developed MDS/AML (odds ratio, 12.3 vs noncarriers). Of these, 7 of 218 had start-lost, 22 of 584 had truncating, and 5 of 257 had missense (odds ratios: 12.9, 15.1, and 7.5, respectively). Using multivariate logistic regression, we found significant associations of DDX41-GPV with MDS, AML, and family history of leukemia but not lymphoma, myeloproliferative neoplasms, or other cancers. We also report that DDX41-GPV carriers do not have an increased prevalence of clonal hematopoiesis (CH). In fact, CH was significantly more common before sporadic vs DDX41-mutant MDS/AML, revealing distinct evolutionary paths. Furthermore, somatic mutation rates did not differ between sporadic and DDX41-mutant AML genomes, ruling out genomic instability as a driver of the latter. Finally, we found that higher mean red cell volume (MCV) and somatic DDX41 mutations in blood DNA identify DDX41-GPV carriers at increased MDS/AML risk. Collectively, our findings give new insights into the prevalence and cognate risks associated with DDX41 variants, as well as the clonal evolution and early detection of DDX41-mutant MDS/AML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Cheloor Kovilakam S, Gu M, Dunn WG, et al. Prevalence and significance of DDX41 gene variants in the general population. Blood. 2023. PMID: 37506341. doi:10.1182/blood.2023020209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。